

**Fermenta Biotech Limited** (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



F.No.:908

February 11, 2025

Corporate Relations  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

Dear Sir,

**Sub: Integrated Filing (Financial) - Unaudited Financial Results for the quarter and nine months ended December 31, 2024**

**Ref: Scrip Code 506414**

Pursuant to Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find enclosed herewith the Integrated Filing (Financial) of the Company for the quarter and nine months ended December 31, 2024 as stated below:

- A) Financial Results – **attached**
- B) Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. – **Not Applicable**
- C) Outstanding default on loans and debt securities – **Not Applicable**
- D) Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter) - **Not Applicable for quarter under consideration.**
- E) Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter) - **Not Applicable for quarter under consideration.**

Kindly take the above on record.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

**Varadvinayak Khambete**

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Factory : Village Takoli, P.O. Nagwain,  
Dist. Mandi - 175 121, Himachal Pradesh, India.  
Tel. : +91-1905-287246 / 48 / 49  
Fax: +91-1905-287250  
Email: info@fermentabiotech.com  
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,  
Taluka - Vagara, Dist: Bharuch - 392 130,  
Gujarat, India.  
Tel. : +91-2641-291440 / 444  
Email: info@fermentabiotech.com  
Website: www.fermentabiotech.com

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Fermenta Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003

*Poonam Todarwal*

per Poonam Todarwal  
Partner

Membership No: 136454

UDIN: 25136454BMOJUD4153

Place: Mumbai

Date: February 11, 2025





**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024**

Sr. No.	Particulars	Standalone						Year Ended Audited March 31, 2024
		Quarter Ended		Nine Months Ended		Year Ended		
		Unaudited December 31, 2024	Unaudited September 30, 2024	Unaudited December 31, 2023	Unaudited December 31, 2024		Unaudited December 31, 2023	
1	<b>Income</b>							
	a) Revenue from operations (refer note 4)	14,625.23	8,954.38	8,935.14	30,849.38	21,743.54	30,709.04	
	b) Other income	222.05	294.68	257.66	779.48	665.65	815.42	
2	<b>Total Income (a+b)</b>	14,847.28	9,249.06	9,192.80	31,628.86	22,409.19	31,524.46	
3	<b>Expenses</b>							
	a) Cost of materials consumed (refer note 8)	3,559.27	3,097.90	1,336.68	9,358.08	5,168.55	8,378.52	
	b) Purchases of stock-in-trade	540.17	323.59	361.81	1,006.84	690.88	778.38	
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	30.03	(535.01)	703.66	(723.80)	1,715.10	1,386.28	
	d) Employee benefits expense	1,574.04	1,422.18	1,347.45	4,450.92	4,025.18	5,393.25	
	e) Finance costs	409.34	369.29	516.43	1,120.96	1,363.72	1,705.21	
	f) Depreciation and amortisation expense	582.02	589.04	612.66	1,757.55	1,749.53	2,369.55	
	g) Other expenses (refer note 5)	3,907.99	3,096.37	2,536.13	10,013.22	7,337.62	11,074.03	
4	<b>Total expenses (a to g)</b>	10,602.86	8,363.36	7,414.82	26,983.77	22,050.58	31,085.22	
5	<b>Profit before Exceptional Items and tax (2-3)</b>	4,244.42	885.70	1,777.98	4,645.09	358.61	439.24	
6	<b>Profit/(Loss) after Exceptional Items and before tax (4-5)</b>	4,244.42	885.70	1,777.98	4,645.09	(541.39)	(900.00)	
7	<b>Tax expense</b>							
	a) Current tax	744.66	70.01	-	814.67	-	168.02	
	b) Adjustment of tax related to earlier years (refer note 7)	-	-	608.27	-	608.27	1,245.55	
	c) Deferred tax charge	-	-	-	-	-	-	
8	<b>Total tax expense (a+b+c)</b>	744.66	70.01	608.27	814.67	608.27	1,413.57	
9	<b>Profit/(Loss) for the period/year after tax (6-7)</b>	3,499.76	815.69	1,169.71	3,830.42	(1,149.66)	(1,874.33)	
	<b>Other Comprehensive Income</b>							
	(A) i) Items that will not be reclassified to Profit or Loss	-	-	-	-	-	12.28	
	ii) Income tax thereon	-	-	-	-	-	-	
	(B) Items that will be reclassified to Profit or Loss (net of tax)	0.82	2.12	(0.43)	3.89	1.06	6.75	
10	<b>Total other comprehensive income/(Loss)</b>	0.82	2.12	(0.43)	3.89	1.06	19.03	
11	<b>Total Comprehensive Income/(Loss) for the period/year (8+9)</b>	3,500.58	817.81	1,169.28	3,834.31	(1,148.60)	(1,855.30)	
12	<b>Other equity (excluding revaluation reserve)</b>	1,457.73	1,449.89	1,443.71	1,457.73	1,443.71	1,443.71	
13	<b>Earnings per equity share of ₹ 5 each (not annualised)</b>							
	a) ₹ Basic	12.05	2.81	4.05	13.23	(0.86)	(3.37)	
	b) ₹ Diluted	12.05	2.81	4.05	13.23	(0.86)	(3.37)	
	<b>Earnings per equity share of ₹ 5 each after exceptional items</b>							
	a) ₹ Basic	12.05	2.81	4.05	13.23	(3.98)	(6.49)	
	b) ₹ Diluted	12.05	2.81	4.05	13.23	(3.98)	(6.49)	



**SIGNED FOR IDENTIFICATION BY**  
  
**S R B C & CO LLP MUMBAI**

See accompanying notes to the Standalone financial results

NOTES:

1. Segment Information

Particulars	Standalone								Year Ended Audited March 31, 2024
	Quarter Ended		Nine Months Ended		Year Ended		Unaudited December 31, 2023	Unaudited December 31, 2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited			
	December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024			
Segment revenue									
- Bulk drugs/chemicals	10,258.89	8,318.23	4,770.74	25,584.36	14,486.30	22,698.29			
- Property (Refer Note 4)	3,837.77	265.86	4,139.30	4,350.61	6,961.33	7,374.15			
- Unallocated	750.62	664.97	282.76	1,693.89	961.56	1,452.02			
Total Income	14,847.28	9,249.06	9,192.80	31,628.86	22,409.19	31,524.46			
Segment results									
- Bulk drugs/chemicals	899.38	1,015.85	(1,708.48)	1,799.98	(4,679.70)	(4,396.46)			
- Property	3,664.35	119.54	3,959.14	3,893.26	6,329.38	6,523.94			
- Unallocated (Net)	90.03	119.60	43.75	72.81	72.65	16.97			
Total Profit before tax and finance cost	4,653.76	1,254.99	2,294.41	5,766.05	1,722.33	2,144.45			
- Finance costs	(409.34)	(369.29)	(516.43)	(1,120.96)	(1,363.72)	(1,705.21)			
Total Profit before Exceptional item and tax	4,244.42	885.70	1,777.98	4,645.09	358.61	439.24			
- Exceptional item (refer note 6)					(900.00)	(900.00)			
Total Profit / (loss) before tax	4,244.42	885.70	1,777.98	4,645.09	(541.39)	(460.76)			
Segment Assets									
- Bulk Drugs/chemicals	50,084.15	48,642.42	45,502.05	50,084.15	45,502.05	45,876.77			
- Property	987.51	1,580.38	2,216.97	987.51	2,216.97	1,481.83			
- Unallocated	8,911.61	4,851.05	10,007.57	8,911.61	10,007.57	9,099.24			
Total Segment Assets	59,983.27	55,073.85	57,726.59	59,983.27	57,726.59	56,457.84			
Segment Liabilities									
- Bulk Drugs/chemicals	9,280.54	8,580.76	6,029.15	9,280.54	6,029.15	7,288.68			
- Property	3,645.43	3,850.02	3,476.22	3,645.43	3,476.22	4,208.26			
- Unallocated	11,926.83	11,144.33	16,096.68	11,926.83	16,096.68	13,538.29			
Total Segment Liabilities	24,852.80	23,575.11	25,602.05	24,852.80	25,602.05	25,035.23			



SIGNED FOR IDENTIFICATION  
By *[Signature]*  
R B C & CO LLP  
MUMBAI

- 2 The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th February, 2025. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the current quarter ended December 31, 2024, the Company has sold part of its investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and accordingly income on sale of such investment property of ₹ 3601.55 lakhs (nine months ended December 31, 2024 is ₹ 3601.65 lakhs; for the quarter ended December 31, 2023 is ₹ 3882.75 and nine months ended December 31, 2023 is ₹ 6195.12 lakhs and for the year ended March 2024 ₹ 6387.82 lakhs) is recognized as income under the head revenue from operations pertaining to property segment.
- 5 Subsequent to the quarter ended December 31, 2024, the Company has entered into a deed of assignment to transfer leasehold land held at Saykha, GIDC Gujrat for transfer value of ₹ 1870 Lakhs. Accordingly a provision for loss amounting to ₹ 480 lakhs has been recorded under the head other expenses.
- 6 During the previous year ended March 31, 2024, considering the prolonged subdued global demands, the Company had revisited its projected future cash flows from its subsidiary Fermenta USA LLC and has determined the value in use of its investments in the said subsidiary. Accordingly, a provision for impairment of investment of ₹ 900 lakhs was recorded as an exceptional item.
- 7 During the previous year ended March 31, 2024, the Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on account of certain disallowances. Accordingly total MAT credit recognised of ₹ 1129.83 lakhs and Tax receivable recognised of ₹ 115.72 lakhs was written off during the previous year relating to such earlier years of which ₹ 608.27 lakhs recorded in quarter ended December 31, 2023.
- 8 During the previous quarter ended September 30, 2024 cost of material consumed includes reversal of provision of ₹ 414.00 lakhs towards the semi-finished inventory used in the production of animal feed.

Place: Thane

Date : 11th February 2025



Prashant Nagre  
Managing Director  
DIN-09165447



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Fermenta Biotech Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

**Holding Company:** Fermenta Biotech Limited

**Subsidiaries:**

- i. Fermenta Biotech (UK) Limited
- ii. Fermenta Biotech GmbH
- iii. Fermenta Biotech USA LLC
- iv. Fermenta USA LLC

**Associate:**

- i. Health and Wellness India Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs 3,268.12 lakhs and Rs. 6,203.03 lakhs, total net profit after tax of Rs. 684.90 lakhs and Rs. 930.59 lakhs, total comprehensive income of Rs. 881.89 lakhs and Rs. 948.41 lakhs for the quarter ended December 31, 2024 and the period ended on that date respectively which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
- 1 subsidiary, whose interim financial results and other financial information reflect total revenues of Rs. Nil and Rs. Nil lakhs, total net profit/(loss) after tax of Rs. (1.57) lakhs and Rs. 0.72 lakhs, total comprehensive income/(loss) of Rs. (1.57) lakhs and 0.72 lakhs, for the quarter ended December 31, 2024 and the period ended on that date respectively
  - 1 associate, whose interim financial results includes the Group's share of total revenues of Rs Nil and Rs. Nil, net profit of Rs. Nil and Rs. Nil, Group's share of total comprehensive income of Rs. Nil and Rs. Nil, for the quarter ended December 31, 2024 and the period ended on that date respectively and net cash outflows of Rs Nil for the period from April 01, 2024 to December 31, 2024.

The unaudited interim financial results and other unaudited financial information of the above subsidiary and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.



# SRBC & COLLP

Chartered Accountants

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For SRBC & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003

*Poonam Tadarwal*

per Poonam Tadarwal  
Partner

Membership No.: 136454

UDIN: **25136454BMOJUE4520**

Place: Mumbai

Date: February 11, 2025







STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Sr. No.	Particulars	Consolidated								Year Ended Audited March 31, 2024
		Quarter Ended		Nine Months Ended		Year Ended		Year Ended Audited March 31, 2024		
		Unaudited December 31, 2024	Unaudited September 30, 2024	Unaudited December 31, 2023	Unaudited December 31, 2024	Unaudited December 31, 2023	Unaudited December 31, 2024			
1	Income	15,646.96	9,502.79	9,896.70	32,962.92	23,832.34	33,566.19			
	a) Revenue from operations (refer note 4)	222.65	288.03	252.39	792.46	642.68	1,180.83			
	b) Other income	15,869.61	9,790.82	10,149.09	33,755.98	24,475.02	34,747.02			
2	Total Income (a+b)	2,255.37	1,866.50	1,280.27	6,841.09	4,730.73	7,700.48			
3	Expenses	2,160.25	1,400.27	832.33	3,978.13	1,968.37	2,701.99			
	a) Cost of materials consumed (refer note 8)	(195.24)	(679.79)	1,041.02	(1,092.57)	2,532.71	2,611.46			
	b) Purchases of stock-in-trade	1,697.95	1,546.18	1,462.40	4,821.70	4,368.53	5,854.79			
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	407.87	369.02	518.54	1,120.11	1,365.68	1,704.60			
	d) Employee benefits expense	608.15	614.93	638.38	1,835.36	1,826.24	2,471.93			
	e) Finance costs	4,401.59	3,491.47	2,768.92	11,128.95	8,018.31	11,946.43			
	f) Depreciation and amortisation expense	11,335.94	8,608.58	8,541.86	28,652.77	24,810.57	34,991.68			
	g) Other expenses (refer note 5)	4,533.67	1,182.24	1,607.23	5,122.61	(742.64)	(244.66)			
4	Total expenses (a to g)	4,533.67	1,182.24	1,607.23	5,122.61	(1,078.19)	(987.30)			
5	Profit/(Loss) before Exceptional Items and tax (2-3)	744.66	70.01	608.27	814.67	608.27	168.02			
6	Exceptional Items (refer note 6)	-	-	-	-	-	-			
7	Profit/(Loss) after Exceptional Items and before tax (4-5)	744.66	70.01	608.27	814.67	608.27	168.02			
	Tax expense	-	-	-	-	-	-			
	a) Current tax	-	-	-	-	-	-			
	b) Adjustment of tax related to earlier years (refer note 7)	-	-	-	-	-	-			
	c) Deferred tax charge	-	-	-	-	-	-			
8	Total tax expense (a+b+c)	744.66	70.01	608.27	814.67	608.27	168.02			
9	Profit/(Loss) for the period after tax but before share of profit/(loss) of an associate (6-7)	3,789.01	1,112.23	998.96	4,307.94	(1,686.46)	(2,400.87)			
10	Share of profit / (loss) of an associate	3,789.01	1,112.23	998.96	4,307.94	(1,686.46)	(2,400.87)			
11	Net Profit/(Loss) after tax (8-9)	3,691.16	1,137.96	984.85	4,247.22	(1,611.91)	(2,305.98)			
	Attributable to:	97.85	(25.73)	14.11	60.72	(74.55)	(94.89)			
	- Owners of the parent	-	-	-	-	-	-			
	- Non-controlling interests	-	-	-	-	-	-			
12	Other Comprehensive Income	-	-	-	-	-	-			
(A)	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-			
	i) Remeasurements of defined benefit plan	-	-	-	-	-	-			
	ii) Income tax thereon	-	-	-	-	-	-			
(B)	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-			
	i) Exchange differences in translating the financials statements of foreign exchange	-	-	-	-	-	-			
	ii) Net fair value change in investment in equity instruments through other comprehensive income (net)	-	-	-	-	-	-			
13	Total other comprehensive income/(Loss)	197.81	(207.52)	(174.70)	21.71	(114.68)	(15.42)			
	Net fair value change in investment in equity instruments through other comprehensive income (net)	3,986.82	904.71	824.26	4,329.65	(1,801.14)	(2,416.29)			
	Attributable to:	3,888.97	990.44	810.15	4,268.93	(1,726.59)	(2,321.40)			
	- Owners of the parent	97.85	(25.73)	14.11	60.72	(74.55)	(94.89)			
	- Non-controlling interests	1,457.73	1,449.89	1,443.71	1,457.73	1,443.71	1,443.71			
14	Paid-up equity share capital (Face value ₹ 5/- per share)	12.71	3.94	3.41	14.67	(3.01)	(5.42)			
15	Other equity (excluding revaluation reserve)	12.71	3.94	3.41	14.67	(3.01)	(5.42)			
16	Earnings per equity share of ₹ 5 each (not annualised)	12.71	3.94	3.41	14.67	(5.59)	(7.99)			
	a) ₹ Basic	12.71	3.94	3.41	14.67	(5.59)	(7.99)			
	b) ₹ Diluted	12.71	3.94	3.41	14.67	(5.59)	(7.99)			



*[Handwritten Signature]*

**SIGNED FOR IDENTIFICATION**  
BY  
**S R B & CO LLP**  
**MUMBAI**

See accompanying notes to the Consolidated financial results

NOTES:

Particulars	Consolidated										Year Ended Audited March 31, 2024
	Quarter Ended			Nine Months Ended			Year Ended			Audited March 31, 2024	
	Unaudited December 31, 2024	Unaudited September 30, 2024	Unaudited December 31, 2023	Unaudited December 31, 2024	Unaudited December 31, 2023	Unaudited December 31, 2023	Unaudited December 31, 2023	Unaudited December 31, 2023			
	₹ in Lakhs										
Segment revenue	11,281.20	8,859.99	5,725.47	27,710.86	16,550.58	25,920.84					
- Bulk drugs/chemicals	3,837.77	265.86	4,139.30	4,350.61	6,961.33	7,374.15					
- Property (Refer Note 4)	750.64	664.97	284.32	1,693.91	963.11	1,452.03					
- Unallocated	15,869.61	9,790.82	10,149.09	33,755.38	24,475.02	34,747.02					
Total Income											
Segment results	1,187.17	1,312.55	(1,877.81)	2,277.06	(5,371.88)	(5,081.40)					
- Bulk drugs/chemicals	3,664.35	1,19.54	3,959.14	3,893.26	6,329.38	6,523.94					
- Property	90.02	119.17	44.44	72.40	72.63	17.40					
- Unallocated (Net)	4,941.54	1,551.26	2,125.77	6,242.72	1,030.13	1,459.94					
Total Profit before tax and finance cost	(407.87)	(369.02)	(518.54)	(1,120.11)	(1,365.68)	(1,704.60)					
- Finance costs	4,533.67	1,182.24	1,607.23	5,122.61	(335.55)	(244.66)					
Total Profit / (Loss) before Exceptional item and tax											
- Exceptional item (refer note 6)											
Total Profit / (loss) before tax	4,533.67	1,182.24	1,607.23	5,122.61	(1,078.19)	(987.30)					
Segment Assets	49,798.91	47,500.20	44,046.74	49,798.91	44,046.74	44,201.98					
- Bulk Drugs/chemicals	987.51	1,580.38	2,216.97	987.51	2,216.97	1,481.83					
- Property	8,911.57	4,851.02	10,015.93	8,911.57	10,015.93	9,099.27					
- Unallocated	59,697.99	53,931.60	56,279.64	59,697.99	56,279.64	54,783.08					
Total Segment Assets											
Segment Liabilities	11,405.75	10,335.25	7,581.49	11,405.75	7,581.49	8,520.60					
- Bulk Drugs/chemicals	3,645.43	3,850.02	3,476.22	3,645.43	3,476.22	4,208.26					
- Property	11,926.43	11,143.92	16,096.50	11,926.43	16,096.50	13,537.91					
- Unallocated	26,977.61	25,329.19	27,154.21	26,977.61	27,154.21	26,266.77					
Total Segment Liabilities											



SIGNED FOR IDENTIFICATION  
BY  
S R B C & CO LLP  
MUMBAI

*(Handwritten signature)*

- 2 The above unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th February, 2025. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the current quarter ended December 31, 2024, the parent company has sold part of its investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and accordingly income on sale of such investment property of ₹ 3601.65 lakhs (nine months ended December 31, 2024 is ₹ 3601.65 lakhs; for the quarter ended December 31, 2023 is ₹ 3882.75 and nine months ended December 31, 2023 is ₹ 6195.12 lakhs and for the year ended March 2024 ₹ 6387.82 lakhs ) is recognized as income under the head revenue from operations pertaining to property segment.
- 5 Subsequent to the quarter ended December 31, 2024, the parent company has entered into a deed of assignment to transfer leasehold land held at Saykha, GIDC Gujrat for transfer value of ₹ 1870 Lakhs. Accordingly a provision for loss amounting to ₹ 480 Lakhs has been recorded under the head other expenses.
- 6 During the previous year ended March 31, 2024, considering the prolonged subdued global demand, the Group had revisited its forecast of future cash flows of the business pertaining to Fermenta USA LLC. Accordingly an impairment of ₹ 742.64 lakhs was recorded against Goodwill created at the time of acquisition of such subsidiary, which has been disclosed as an exceptional item
- 7 During the previous year ended March 31, 2024, the parent Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on account of certain disallowances. Accordingly total MAT credit recognised of ₹ 1129.83 lakhs and Tax receivable recognised of ₹ 115.72 lakhs was written off during the previous year relating to such earlier years of which ₹ 608.27 lakhs recorded in quarter ended December 31, 2023.
- 8 During the previous quarter ended September 30, 2024 cost of material consumed includes reversal of provision of ₹ 414.00 lakhs towards the semi-finished inventory used in the production of animal feed.

Place: Thane

Date : 11th February 2025

Prashant Nagre  
Managing Director  
DIN-09165447

